Author of the publication

copy delete add this publication to your clipboard
community post
history of this post
URL
DOI
BibTeX
EndNote
APA
Chicago
DIN 1505
Harvard
MSOffice XML

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors

A. Petit, J. Rak, M. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R. Kerbel. Am.J.Pathol., 151 (6): 1523-1530 (1997)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

S. R. Keshava

Paul Kerbel

Maxim Kerbel

Harald Kerbel

Sylvia Kerbel

Other publications of authors with the same name

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumorsA. Petit, J. Rak, M. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R. Kerbel. Am.J.Pathol., 151 (6): 1523-1530 (1997)Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesisY. Shaked, F. Bertolini, S. Man, M. Rogers, D. Cervi, T. Foutz, K. Rawn, D. Voskas, D. Dumont, Y. Ben-David and 6 other author(s). Cancer Cell, 7 (1): 101-111 (2005)Tumor angiogenesisR. Kerbel. N.Engl.J.Med., 358 (19): 2039-2049 (2008)A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasmaJ. Ebos, G. Bocci, S. Man, P. Thorpe, D. Hicklin, D. Zhou, X. Jia, and R. Kerbel. Mol.Cancer Res., 2 (6): 315-326 (2004)Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodiesG. Bocci, S. Man, S. Green, G. Francia, J. Ebos, J. Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe and 4 other author(s). Cancer Res., 64 (18): 6616-6625 (2004)Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growthJ. Ebos, C. Lee, E. Bogdanovic, J. Alami, S. Van, G. Francia, P. Xu, A. Mutsaers, D. Dumont, and R. Kerbel. Cancer Res., 68 (2): 521-529 (2008)Molecular and cellular biomarkers for angiogenesis in clinical oncologyF. Bertolini, P. Mancuso, Y. Shaked, and R. Kerbel. Drug Discov.Today, 12 (19-20): 806-812 (2007)Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyJ. Ebos, C. Lee, J. Christensen, A. Mutsaers, and R. Kerbel. Proc.Natl.Acad.Sci.U.S.A, 104 (43): 17069-17074 (2007)

BibSonomy

Disambiguation of "Kerbel, R. S."